The UK’s Royal Hospital for Neuro-disability and the East Kent Hospitals University NHS Foundation Trust have tapped Sanome’s MEMORI platform to support the earlier detection of hospital-acquired infections (HAI) and clinical decision-making protocols.
Using AI, Memori analyses real-time patient data to identify emerging infection risk. According to Sanome, early studies of the platform have demonstrated its ability to make life-threatening HAI predictions up to three days earlier than standard practice.
Memori is designed to integrate into electronic patient records (EPR), thereby bringing the tool’s insights into clinicians’ existing workflows.
The Royal Hospital for Neuro-disability’s integration of Sanome’s tool makes it the first specialist neuro facility to embed Memori into routine patient care. Research indicates that patients with complex neurological conditions are among the most vulnerable to infections and associated complications during hospital stays, especially within intensive care units (ICU). Common HAIs include urinary tract infection (UTI) and pneumonia.
East Kent Hospitals is also integrating Memori into its EPRs. According to Sanome, the collaborations lay the groundwork for a scalable new model. In August, Memori became the UK’s first multimodal Class IIb CE-marked AI Software as a Medical Device (SaMD) for infection prediction.
Sanome expects Memori to be launched at the two sites in the coming months and plans to make additional NHS deployments of Memori throughout 2026.
Sanome CEO Benedikt von Thüngen commented: “Partnering with leading healthcare organisations like the Royal Hospital for Neuro-disability and East Kent Hospitals University NHS Foundation Trust marks another major step towards bringing earlier, data-driven infection detection into everyday care for every patient.
“Our aim is to equip frontline teams with the actionable insights they need to intervene sooner and protect patients, at the same time relieving pressure on already-stretched resources.”
HAIs represent a significant threat to hospitals and healthcare systems, with research from BMJ Journals indicating that HAIs cost the NHS around £2.7bn ($3.59bn) annually. In addition, data from the US Centers for Disease Control and Prevention (CDC) has estimated that on any given day, approximately one in 31 hospital patients in the US has at least one HAI. In 2015, the CDC estimated that there were 687,000 HAIs in US acute care hospitals, with around 72,000 hospital patients with HAIs dying during their hospitalisations.
